Type 2 diabetes is one of the most frequent diseases among women, especially in certain stages of life such as menopause.This is explained to DM Sharona Azriel, an attached doctor of the Endocrinology and Nutrition Service of the Infanta Sofía University Hospital and the University Hospital Pozuelo, both from Madrid."Diabetes is one of chronic noncommunicable diseases that has undergone a greater increase in its prevalence in recent years: in Spain it affects 13.8% of the population according to the data of the study di@bet.es published in 2012", Azriel details.
This same report reveals that, although type 2 diabetes is more frequent in men, increased age and living in a low socioeconomic environment influence more negatively in the female population and increase the possibility of developing the disease."There are certain stages of life, such as menopause, in which abdominal fat increases, which means a greater risk factor," he clarifies.
In this sense, the study di@bet.es suggests that higher economic income is also perceived of hypertension and cholesterol in the female."It is important to comment that women with diabetes have more physical and cognitive limitations than men, and comorbidities such as depression, because they are more aware of the family environment and, therefore, have less self -care and less therapeutic adherence," he says.
In general terms, 44 cases of type 2 diabetes are diagnosed every hour in Spain, according to the latest data presented recently at the Annual Congress of the Spanish Diabetes Society.
For this endocrinologist it is essential to follow the European guides that determine the diagnostic criteria and patient treatments.However, to reach an early detection, both of the disease and the comorbidities it presents, Azriel considers that “the relationship between primary care and hospital must be fluid, and specialized care must facilitate the primary doctor information on situations on situationsin which screenings and derivations are necessary ”.
"We entered a new era with antiobesity drugs that are directed against hormones such as LPG-1"
Despite these improvement lines, this specialist estimates that in most cases, common derivations and protocols are established to have standardized when patients must be referred."There are a number of criteria for which we know that a screening is needed: blood pressure, overweight, low or high triglyceridic HDL levels."
In the case of the female population, he warns that “it is important that every woman who has presented a gestational diabetes or has a history of fetal macrosomia is subjected to a control from primaryto prevent type 2 diabetes ”.
Therapeutic advances in diabetes
In his opinion, the management of the disease has experienced a real revolution from the therapeutic point of view with the commercialization of new drugs and molecules that go beyond glycemic control because they have demonstrated cardiovascular and renal benefits."The therapeutic innovations in the treatment of type 2 diabetes are based mainly on drugs of two groups: the glucosuric or inhibitors of the type 2 glucotransporter sodium and the antagonists of DGT-1 receptors", which are of weekly or daily administrationParenteral
"Diabetes is one of chronic noncommunicable diseases that has suffered a greater increase in its prevalence"
A new DGT1 receptor agonist of weekly administration with a high metabolic power is about to reach the market “which has shown a greatEffectiveness in reducing glucosylated hemoglobin, weight and voltage reduction, as well as stroke in patients with 2 diabetes who have suffered a cardiovascular event ”.
With respect to new therapeutic targets, other lines aimed at one of the main risk factors are being made through: obesity."We are starting a new era with drugs that are directed against hormones such as LPG-1 and that are demonstrating very hopeful results in obesity because they are getting weight decreases of up to 11 kilos," he says.In his opinion, in the coming years very good results could be obtained with these types of medications and even that associations are raised where the same molecule contains basal insulin and agonist LPG-1 with optimal metabolic benefits.
